Pharmacogenomic Study of SARS-CoV-2 Treatments: Identifying Polymorphisms Associated with Treatment Response in COVID-19 Patients

<b>Background/Objectives</b>: The COVID-19 pandemic resulted in 675 million cases and 6.9 million deaths by 2022. Despite substantial declines in case fatalities following widespread vaccination campaigns, the threat of future coronavirus outbreaks remains a concern. Current treatments f...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Biomedicines
المؤلفون الرئيسيون:	Alexandre Serra-Llovich, Natalia Cullell, Olalla Maroñas, María José Herrero, Raquel Cruz, Berta Almoguera, Carmen Ayuso, Rosario López-Rodríguez, Elena Domínguez-Garrido, Rocio Ortiz-Lopez, María Barreda-Sánchez, Marta Corton, David Dalmau, Esther Calbo, Lucía Boix-Palop, Beatriz Dietl, Anna Sangil, Almudena Gil-Rodriguez, Encarna Guillén-Navarro, Esther Mancebo, Saúl Lira-Albarrán, Pablo Minguez, Estela Paz-Artal, Gladys G. Olivera, Sheila Recarey-Rama, Luis Sendra, Enrique G. Zucchet, Miguel López de Heredia, Carlos Flores, José A. Riancho, Augusto Rojas-Martinez, Pablo Lapunzina, Ángel Carracedo, María J. Arranz, SCOURGE COHORT GROUP
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	MDPI AG 2025-02-01
الموضوعات:	SARS-CoV-2 pharmacogenetics corticoids immunomodulators precision medicine
الوصول للمادة أونلاين:	https://www.mdpi.com/2227-9059/13/3/553